Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 26% ± 10% | |
fibroblast | 10 studies | 34% ± 17% | |
natural killer cell | 6 studies | 28% ± 10% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 22% ± 11% | |
adipocyte | 4 studies | 20% ± 4% | |
cholangiocyte | 3 studies | 44% ± 19% | |
glomerular endothelial cell | 3 studies | 40% ± 0% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 30% ± 12% | |
mesothelial cell | 3 studies | 33% ± 13% | |
retina horizontal cell | 3 studies | 25% ± 8% | |
GABAergic neuron | 3 studies | 27% ± 8% | |
glutamatergic neuron | 3 studies | 30% ± 5% |
Insufficient scRNA-seq data for expression of PDGFD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 13732.56 | 258 / 258 | 95% | 41.65 | 218 / 230 |
pancreas | 100% | 1850.80 | 327 / 328 | 94% | 27.70 | 167 / 178 |
breast | 99% | 3090.91 | 456 / 459 | 92% | 20.67 | 1031 / 1118 |
thymus | 100% | 3700.11 | 652 / 653 | 91% | 22.12 | 551 / 605 |
prostate | 85% | 1116.40 | 208 / 245 | 86% | 10.70 | 431 / 502 |
ovary | 100% | 7281.01 | 180 / 180 | 69% | 8.54 | 297 / 430 |
kidney | 69% | 664.71 | 61 / 89 | 93% | 56.97 | 834 / 901 |
stomach | 95% | 1487.64 | 340 / 359 | 61% | 6.69 | 174 / 286 |
skin | 71% | 1536.25 | 1289 / 1809 | 70% | 18.26 | 330 / 472 |
bladder | 76% | 1663.95 | 16 / 21 | 50% | 5.50 | 252 / 504 |
uterus | 84% | 1408.76 | 142 / 170 | 42% | 5.38 | 191 / 459 |
intestine | 63% | 651.86 | 605 / 966 | 48% | 5.26 | 253 / 527 |
blood vessel | 100% | 6951.74 | 1329 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 3394.57 | 1194 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 2025.34 | 826 / 861 | 0% | 0 | 0 / 0 |
lung | 35% | 308.64 | 200 / 578 | 57% | 6.72 | 660 / 1155 |
esophagus | 28% | 338.92 | 409 / 1445 | 49% | 5.08 | 89 / 183 |
lymph node | 0% | 0 | 0 / 0 | 69% | 17.67 | 20 / 29 |
liver | 2% | 16.99 | 4 / 226 | 48% | 15.25 | 195 / 406 |
brain | 4% | 35.68 | 117 / 2642 | 43% | 6.14 | 301 / 705 |
eye | 0% | 0 | 0 / 0 | 35% | 4.36 | 28 / 80 |
tonsil | 0% | 0 | 0 / 0 | 16% | 1.05 | 7 / 45 |
spleen | 14% | 90.66 | 34 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 13% | 112.03 | 118 / 929 | 0% | 0 | 0 / 0 |
muscle | 6% | 49.00 | 50 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051781 | Biological process | positive regulation of cell division |
GO_0071673 | Biological process | positive regulation of smooth muscle cell chemotaxis |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0072126 | Biological process | positive regulation of glomerular mesangial cell proliferation |
GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
GO_0043406 | Biological process | positive regulation of MAP kinase activity |
GO_0048008 | Biological process | platelet-derived growth factor receptor signaling pathway |
GO_2000439 | Biological process | positive regulation of monocyte extravasation |
GO_0050730 | Biological process | regulation of peptidyl-tyrosine phosphorylation |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0071230 | Biological process | cellular response to amino acid stimulus |
GO_0031954 | Biological process | positive regulation of protein autophosphorylation |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0036120 | Biological process | cellular response to platelet-derived growth factor stimulus |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005161 | Molecular function | platelet-derived growth factor receptor binding |
GO_0008083 | Molecular function | growth factor activity |
Gene name | PDGFD |
Protein name | Platelet derived growth factor D Platelet-derived growth factor D (PDGF-D) (Iris-expressed growth factor) (Spinal cord-derived growth factor B) (SCDGF-B) [Cleaved into: Platelet-derived growth factor D, latent form (PDGFD latent form); Platelet-derived growth factor D, receptor-binding form (PDGFD receptor-binding form)] |
Synonyms | IEGF UNQ1899/PRO4345 MSTP036 SCDGFB |
Description | FUNCTION: Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays an important role in wound healing. Induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Can initiate events that lead to a mesangial proliferative glomerulonephritis, including influx of monocytes and macrophages and production of extracellular matrix (By similarity). . |
Accessions | ENST00000529268.1 H0YD37 ENST00000302251.9 [Q9GZP0-2] Q9GZP0 ENST00000393158.7 [Q9GZP0-1] |